Key result
Sulfinpyrazone marginally reduces cardiac mortality vs placebo, driven by fewer sudden deaths within six months.
Why the study?
The Anturane Reinfarction Trial was conducted to evaluate the effect of sulfinpyrazone on cardiac mortality after myocardial infarction.
Does sulfinpyrazone reduce cardiac mortality in patients after myocardial infarction?
RCT (n=1,558)
double-blind
randomized
Yes
Does sulfinpyrazone reduce cardiac mortality in patients after myocardial infarction?
p-value: p=0.058
Sulfinpyrazone showed a borderline reduction in cardiac mortality post-myocardial infarction, primarily driven by a decrease in sudden death during the first six months of treatment.
Borderline post-MI cardiac mortality reduction does not alter practice; leaves open confirmation of early sudden death benefit.
The Anturane Reinfarction Trial, reported previously in the Journal, 1 , 2 was a randomized double-blind multicenter trial comparing the effects of sulfinpyrazone and a placebo on cardiac mortality after myocardial infarction. In this study, 1558 eligible patients were followed for an average of 16 months, beginning 25 to 35 days after infarction. A reduction in overall cardiac mortality was observed (P = 0.058), but this benefit occurred entirely during the first six months of treatment and appeared to be attributable to a decrease in the incidence of sudden death.Subsequently, a critique of this study by the FDA was published, also in . . .
No takes yet. Share an insight, caveat, or question.
A 1982 study conducted an RCT in myocardial infarction (n=1,558). sulfinpyrazone vs. placebo was evaluated on cardiac mortality (p=0.058). Sulfinpyrazone reduced overall cardiac mortality compared to placebo (P=0.058), with the benefit occurring entirely during the first six months and attributable to a decrease in sudden death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: